Skip to main content
Premium Trial:

Request an Annual Quote

VizX Aims at Becoming Cash-Flow Positive by End of Year

NEW YORK, July 24 - Informatics company VizX labs intends to be cash-flow positive at the end of the year, according to an e-mail message from CEO and co-founder Thomas Ranken.


"We will develop the capacity to expand our company from new funding sources: earnings, investment, and debt," said Ranken.


VizX makes the gene expression-analysis software, a new version of which was launched earlier this month. Besides becoming cash-flow positive, Ranken said the company's "top priority" is to "build sales" for the software, which he said is responsible for the lion's share of the company's revenue.


Reached by telephone in VizX's Seattle, Wash., headquarters, Ranken said the firm intends to increase its sales staff and enter into new distribution deals.


VizX has been funded by angel investors up until now, Ranken said. He added the company is wrapping up a convertible-note round, and is talking to venture capitalists. "But ... the market is very tough."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.